OctoPlus, The Medicines Company Sign Pharma Manufacturing, Development Agreement
As per the terms of the agreement, OctoPlus is expected to perform process development and clinical manufacturing for The Medicines Company related to MDCO-216 (ApoA-I Milano/phospholipid complex). MDCO-216
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.